prIME Downloadable Slides from the 2011 Annual Breast Cancer Meeting in San Antonio

prIME Downloadable Slides from the 2011 Annual Breast Cancer Meeting in San Antonio

prIME Oncology invites you to view prIME Downloadable Slides in Advanced Breast Cancer and Early Breast Cancer that focus on new breast cancer data just released from the 2011 Annual Breast Cancer Meeting in San Antonio.

Target Audience
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, and other healthcare providers involved and/or interested in the care of patients with breast cancer.

Educational Objectives
Upon completion of this educational activity, participants should be able to: Summarize the most recent clinical trial data regarding novel therapeutic options for the management of breast cancer Compare and contrast the efficacy and tolerability of various therapies and therapeutic combinations available for the treatment of breast cancer

Click here to view the downloadable slides

This slide deck covers newly released data in advanced breast cancer focusing on the following data releases:

Abstract S3-7: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial

Abstract S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Abstract S5-5: A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA)

Abstract S5-7: A phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer

Abstract P5-19-03: Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Overall survival and safety analysis of a randomized phase II trial

This slide deck covers newly released data in early breast cancer focusing on the following data releases:

Abstract S1-2: Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer

Abstract S1-3: Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST

Abstract S2-3: NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis

Abstract S4-6: A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194.

Abstract S5-6: Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA)

Click here to view the downloadable slides

This activity is supported by Genentech.

Target Audience

Educational Objectives